Ashwagandha (Withania somnifera) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND)
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by progressive dysfunction of memory and higher cognitive functions with abnormal accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout cortical and limbic brain regions. At present no curative treatment is available, and research focuses on drugs for slowing disease progression or providing prophylaxis. Withania somnifera (WS) also known as 'ashwagandha' is used widely in Ayurvedic medicine as a nerve tonic and memory enhancer. However, there is a paucity of data on the potential neuroprotective effects of W.somnifera against β-Amyloid (1-42)-induced neuropathogenesis. In the present study, we have tested the neuroprotective effects of methanol:Chloroform (3:1) extract of ashwagandha against β-amyloid induced toxicity and HIV-1Ba-L (clade B) infection using a human neuronal SK-N-MC cell line. Our results showed that β-amyloid induced cytotoxic effects in SK-N-MC cells as shown by decreased cell growth when tested individually. Also, confocal microscopic analysis showed decreased spine density, loss of spines and decreased dendrite diameter, total dendrite and spine area in clade B infected SK-N-MC cells compared to uninfected cells. However, when ashwagandha was added to β-amyloid treated and HIV-1 infected samples, the toxic effects were neutralized. Further, the MTT cell viability assays and the peroxisome proliferator-activated receptor-γ (PPARγ) levels supported these observations indicating the neuroprotective effect of WS root extract against β-amyloid and HIV-1Ba-L (clade B) induced neuro-pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“The pathological hallmarks are complex and include neuronal degeneration (cholinergic neurons in particular), abnormal neurofibrillary tangles, toxic β-amyloid (AB) plaques, decline of neurochemicals which are essential for neuronal transmission and neuro-inflammation [4-6].”
BackgroundHydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074 · cited 1×
“by free radicals and oxidative stress [28,49-53].”
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 3×
“Michaelis et al [26] used 5 and 10 μM concentration on cortical cell cultures whereas Yankner et al [27] used 20 μM on hippocampal neurons.”
BackgroundMethodTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 2×
“familial cases are caused primarily by mutations in three genes namely, amyloid precursor protein (APP), presenilin1 (PS1), and presenilin 2 (PS2) [10].”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
The Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Control of Macrophage Activation and Function by PPARs
Chawla, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.216523 · Cited by 531 · cited 1×
“In general, β-amyloid deposition elicits a vigorous “M1” microglia-mediated inflammatory response contributing to disease progression [71-73].”
BackgroundA Hundred Years of Alzheimer's Disease Research
Hardy, J. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.016 · Cited by 467
Withania somnifera: an Indian ginseng
Kulkarni, S. K., & Dhir, A. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.011 · Cited by 416 · cited 1×
“) Dunal, also known as ‘ashwagandha’ (ASH) in Sanskrit and as ‘Indian ginseng’ is a multipurpose medicinal plant with remarkable increase in recent years in the pharmacological studies, as it has been shown to possess wide spectrum of therapeutic properties such as nerve tonic, memory enhancer, antistress, immunomodul…”
BackgroundNatural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390 · cited 1×
“A recent study of oral administration of a semi-purified extract of the root of Withania somnifera consisting predominantly of withanolides and withanosides reversed behavioral deficits, plaque pathology, accumulation of β-amyloid peptides (Aβ) and oligomers in the brains of middle-aged and old APP/PS1 Alzheimer’s dis…”
BackgroundChinetti-Gbaguidi, G., Baron, M., Bouhlel, M. A., Vanhoutte, J., Copin, C., Sebti, Y., Derudas, B., Mayi, T., Bories, G., Tailleux, A., et al. (2011) · Circulation Research · doi:10.1161/circresaha.110.233775 · Cited by 387 · cited 1×
“In general, β-amyloid deposition elicits a vigorous “M1” microglia-mediated inflammatory response contributing to disease progression [71-73].”
BackgroundMatrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 1×
“angiotensin-converting enzyme, plasminogen activator and matrix metalloproteinase-9 [58-62].”
BackgroundMandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355 · cited 1×
“The peroxisome proliferator-activated receptor-γ (PPARγ) is a ligand-activated nuclear receptor and its activation is associated with clearance of β-amyloid and ameliorating the pathologic and behavioral deficits in AD [70].”
BackgroundNeuritic regeneration and synaptic reconstruction induced by withanolide A
Kuboyama, T., Tohda, C., & Komatsu, K. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706122 · Cited by 339 · cited 1×
“Withanolide A and withanoside IV from roots help to promote neurite outgrowth in cultured neurons and in rodents injected with Aβ 25–35 [18].”
BackgroundBrain deposition of beta-amyloid is a common pathologic feature in HIV positive patients
Green, D. A., Masliah, E., Vinters, H. V., Beizai, P., Moore, D. J., & Achim, C. L. (2005) · AIDS · doi:10.1097/01.aids.0000161770.06158.5c · Cited by 299 · cited 1×
“A significant increase in brain APP in AIDS, specifically in the axons present in the subcortical white matter tracts have been described by several investigators [11-13].”
BackgroundBhattacharya, A., Ghosal, S., & Bhattacharya, S. K. (2001) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(00)00309-3 · Cited by 288
Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease
Ohyagi, Y., Asahara, H., Chui, D.-H., Tsuruta, Y., Sakae, N., Miyoshi, K., Yamada, T., Kikuchi, H., Taniwaki, T., Murai, H., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2637fje · Cited by 281
Reversal of long-term dendritic spine alterations in Alzheimer disease models
Smith, D. L., Pozueta, J., Gong, B., Arancio, O., & Shelanski, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908706106 · Cited by 229 · cited 2×
“Altered cellular morphology and architecture in β-amyloid (Figure 6B) as well as β-amyloid plus ashwagandha (Figure 6D) and control (Figure 6A) and only ashwagandha (Figure 6C) treated SK-N-MC cells were captured using confocal microscopy and morphological changes were analyzed using the established protocol [35].”
MethodNeuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats
Ahmad, M., Saleem, S., Ahmad, A. S., Ansari, M. A., Yousuf, S., Hoda, M. N., & Islam, F. (2005) · Human & Experimental Toxicology · doi:10.1191/0960327105ht509oa · Cited by 227 · cited 1×
“Numerous studies over the past two decades indicated that Withania somnifera (WS) has anti-inflammatory, anti-tumor, anti-stress, anti-oxidant, mind boosting and rejuvenating properties [38-40].”
BackgroundA comparative pharmacological investigation of Ashwagandha and Ginseng
Grandhi, A., Mujumdar, A. M., & Patwardhan, B. (1994) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(94)01119-2 · Cited by 142 · cited 1×
“Structurally, withanolides consist of a steroid backbone bound to a lactone and have resemblance in their structure and action to ginsenosides, the active constituents of Asian ginseng, Panax ginseng [44].”
BackgroundNeuroprotective Effects of Withania somnifera Dunn. in Hippocampal Sub‐regions of Female Albino Rat
Jain, S., Shukla, S. D., Sharma, K., & Bhatnagar, M. (2001) · Phytotherapy Research · doi:10.1002/ptr.802 · Cited by 101
Cited by
Pharmacologic overview of Withania somnifera, the Indian Ginseng
Dar, N. J., Hamid, A., & Ahmad, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2012-1 · Cited by 370
Ethnomedicinal uses of the local flora in Chenab riverine area, Punjab province Pakistan
Umair, M., Altaf, M., Bussmann, R. W., & Abbasi, A. M. (2019) · Journal of Ethnobiology and Ethnomedicine · doi:10.1186/s13002-019-0285-4 · Cited by 342
Mikulska, P., Malinowska, M., Ignacyk, M., Szustowski, P., Nowak, J., Pesta, K., Szeląg, M., Szklanny, D., Judasz, E., Kaczmarek, G., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041057 · Cited by 324
Paul, S., Chakraborty, S., Anand, U., Dey, S., Nandy, S., Ghorai, M., Saha, S. C., Patil, M. T., Kandimalla, R., Proćków, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112175 · Cited by 306
Choudhary, D., Bhattacharyya, S., & Bose, S. (2017) · Journal of Dietary Supplements · doi:10.1080/19390211.2017.1284970 · Cited by 215
Metadata
- Authors
- Kurapati, K. R. V., Atluri, V. S. R., Samikkannu, T., & Nair, M. P. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-16
- Volume
- 8
- Issue
- 10
- Pages
- e77624
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1996636308
- Cited by
- 129
- References
- 24
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.